Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy
- 1 December 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (13-14) , 2174-2180
- https://doi.org/10.1016/0959-8049(95)00483-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood DisordersPharmacoEconomics, 1994
- Economic Costs of Theophylline ToxicityPharmacoEconomics, 1994
- Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working GroupJAMA, 1993
- Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicityCancer Treatment Reviews, 1993
- Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial.Journal of Clinical Oncology, 1991
- Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.Journal of Clinical Oncology, 1988
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Cancer Statistics, 1987CA: A Cancer Journal for Clinicians, 1987
- Confidence intervals rather than P values: estimation rather than hypothesis testing.BMJ, 1986
- Origin of Infection in Acute Nonlymphocytic LeukemiaAnnals of Internal Medicine, 1972